Pharmalink wins US orphan designation for Busulipo
This article was originally published in Scrip
Executive Summary
Pharmalink, a Swedish specialty company, has received orphan drug designation from the US FDA for its transplant conditioning agent Busulipo (busulfan), which the company plans to file in late 2014.